Triphenylalkene derivatives and their use as selective estrogen receptor modulators
Granted 20 Apr 2004 · no office action yet
Current assignee: FORENDO PHARMA LTD · originally HORMOS MEDICAL OY LTD.
Law firm: Law firm · Log in to unlock
Attorney: Attorney · Log in to unlock
Inventors: Arja Kalapudas, Risto Lammintausta, Kalervo Vnnen, Pirkko Hrknen +2 · Examiner: Alan L. Rotman
Life of the patent
4 dated eventsAbstract
The invention provides novel selective estrogen receptor modulator compounds of the general formula: wherein R1 and R2 , which are the same or different area) H, halogen, OCH3, OH; or where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H,CH2CCH or CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; orc) Y(CH2)nCH2OR6where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, CH2CH2OH, or CH2CH2Cl; ord) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; andR3 is H, halogen, OH or OCH3;stereoisomers thereof and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.
Claims
8 · 8 independent · depth 1Classifications
20 codes- A61K3/1445
Claim changes
SoonSee which claims were amended, added or cancelled during examination, with every added and removed word marked.
The published claims of this patent are not paired with the granted ones in what we hold.
File wrapper
See the full prosecution history — every USPTO and applicant action on this file, in order.
Log in to unlockTerm & fees
See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.
Log in to unlockPriority chain
2 priority documents›Priority documents — 2
| Type | Document | Date |
|---|---|---|
| provisional | US 60/165828 00 | 16 Nov 1999 |
| related publication | US 20030225130 A1 | 4 Dec 2003 |
Validity challenges
See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.
Log in to unlockCitations
See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.
Log in to unlock